 |
 |
|||||
|
|
|||||
|
||||||
|
||||||
|
EXFORGE
New pill means millions of UK sufferers could reach their target blood pressure Exforge offers significant reductions in blood pressure to help UK sufferers achieve goal
There are 5 million people currently being treated for high blood pressure in the UK who could benefit from a new drug launched today.
Exforge significantly lowers blood pressure in patients with mild to moderate and severe hypertension - it has been proven to deliver blood pressure drops of up to 36/29mmHg in patients with severe hypertension
According to leading clinical pharmacologists and cardiologists those sufferers who are not meeting targets set by UK leading experts at the British Hypertension Society and by the National Institute of Clinical Excellence are "Under-treated Hypertensives" and have an increased risk of heart attack, stroke, heart and kidney failure and premature death. Exforge, a combination pill launched today could help these patients to achieve their target.
As hypertension often doesn't have any symptoms, the only way for an individual to find out if they have high blood pressure is by having it measured - meaning often there are individuals who are unaware that their blood pressure levels are higher than recommended. Hypertension, or high blood pressure, is diagnosed when the pressure in an individual's blood vessels is found to be consistently high on a number of occasions.
High blood pressure is a key risk factor for cardiovascular disease (CVD) that includes both coronary heart disease and stroke. It is estimated that there are 62,000 unnecessary deaths every year through stroke and ischeamic heart disease.
Novartis has launched combination amlodipine besylate/valsartan (Exforge) tablets for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.
The basic NHS price for a pack of 28 tablets is as follows:
* Exforge 5 mg/80 mg (amlodipine/valsartan) film-coated tablets (£16.44)
* Exforge 5 mg/160 mg film-coated tablets (£21.66)
* Exforge 10 mg/160 mg film-coated tablets (£21.66)
Clinical paper attached and a link to another below.
http://www.clinicaltherapeutics.com/xpress.html?27270996.676418465
A study of mild to moderate hypertensive patients compared amlodipine
10mg and valsartan 160mg. In this population (DBP >90 <110) the
BP reductions were 17.7/14.3 and 16.6/14.3 respectively after 12 weeks.
There was no significant difference between the groups.
Fogari et al. Am J Hypertens 2005;18:P521
home | help | contact | e-mail
Copyright www.Age-Net.co.uk 2000 - 2008
